veliparib + capecitabine

**Veliparib + capecitabine** is an experimental oral drug combination evaluated in oncology, particularly for locally advanced rectal cancer and other solid tumors. **Veliparib** is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) 1 and 2, which impairs DNA damage repair and potentiates the cytotoxic effects of DNA-damaging therapies. **Capecitabine** is an oral prodrug converted to 5-fluorouracil, an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis in cancer cells. Used together, this combination is studied as part of chemoradiation regimens for enhanced tumor response and improved outcomes.[1][3]